Clinical Trials Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Mar 7, 2016; 22(9): 2837-2843
Published online Mar 7, 2016. doi: 10.3748/wjg.v22.i9.2837
Figure 1
Figure 1 Expression of sal-like protein 4 in liver tissues. A: Expression of sal-like protein 4 (SALL4) in liver hemangioma tissue (Maxvision, magnification × 200); B: Expression of SALL4 in adjacent noncancerous cirrhotic tissue (Maxvision, magnification × 400); C: Expression of SALL4 in hepatocellular carcinoma tissue (Maxvision, magnification × 400).
Figure 2
Figure 2 Survival analysis. A: Survival analysis correlated with expression of SALL4 in postoperative hepatocellular carcinoma patients; B: Survival analysis of postoperative hepatocellular carcinoma patients correlated with combinedα-fetoprotein level and SALL4 expression; C: Survival analysis of SALL4-positive hepatocellular carcinoma patients correlated with α-fetoprotein. AFP: α-fetoprotein; SALL4: Sal-like protein 4.